U-CyTech Overview

  • Founded
  • 1999

  • Status
  • Private

  • Employees
  • 4

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 1

U-CyTech General Information


Developer of biomedical products designed to offer immunoassays for human, monkey, and rodent use. The company's products include cytokine enzyme-linked immunosorbent assays, T and B cell assays, and enzyme-linked Immuno spot systems which are designed for the ex vivo detection of individual protein-secreting cells, enabling clients to prepare efficient medicines for their biological research.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Yalelaan 48
  • 3584 CM Utrecht
  • Netherlands
+31 085 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

U-CyTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jan-1999 Completed Generating Revenue
To view U-CyTech’s complete valuation and funding history, request access »

U-CyTech Patents

U-CyTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1372702-B1 Treatment of hypoxia/ischaemia related blood flow resistance using beta-interferon Inactive 03-Apr-2001 0000000000
US-20040136957-A1 Administering a therapeutically relevant dose of ifn (interferon) type-i or a functional part, derivative and/or analogue thereof Inactive 03-Apr-2001 0000000000
US-20040105843-A1 Prevention of cellular damage in disease resulting from h/i-related blood flow resistance due to occlusion of blood vessels Inactive 03-Apr-2001 0000000000
AU-2002249692-A1 Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation Inactive 03-Apr-2001 0000000000
DE-60129472-D1 Treatment of hypoxya / ischaemia blood flow resistance with beta-interferon Inactive 03-Apr-2001 A61K38/212
To view U-CyTech’s complete patent history, request access »

U-CyTech Executive Team (2)

Name Title Board Seat Contact Info
Peter Van der Meide Ph.D Founder, Owner & Co-Chief Executive Officer
Nicole Besouw Ph.D Co-Chief Executive Officer
To view U-CyTech’s complete executive team members history, request access »

U-CyTech Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

U-CyTech Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Utrecht Holdings Not-For-Profit Venture Capital Minority 000 0000 000000 0
To view U-CyTech’s complete investors history, request access »